Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice.

ABSTRACT:

Background

There is substantial evidence that patients with ankylosing spondylitis (AS) have high response rates to tumour necrosis factor inhibitors (TNFi), a low likelihood of successful treatment termination, but yet a limited drug retention. Whereas several reports have assessed drug retention rates for TNFi in AS, there are few, if any, studies investigating the actual treatment trajectories on a patient level, including subsequent therapy changes and dose reductions, of individual patients. The aim of this study was to describe 5-year treatment trajectories in patients with ankylosing spondylitis (AS) starting a first TNFi.

Methods

Bio-naïve patients with AS starting a TNFi in 2006-2015 were identified in the nationwide Swedish Rheumatology Quality register and followe

SUBMITTER: Lindstrom U 

PROVIDER: S-EPMC6540538 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature